Class summary at a glance.

Every drug in the Anti-anginal class tracked across NADAC, Part D Formulary, Part D Spending, FDA Orange Book, and shortage data. Ranked below by CY24 Part D spend. Click any molecule for the full drug profile.

Molecules in class: 1tracked in Part D
CY24 Part D spend: $162.9Mcombined across class
Total Rx claims: 1.9M559K unique beneficiaries
Generic mfrs (active): 20across all molecules

Every drug in this class, ranked by Part D spend.

CY2024 dataCMS Part D Spending Dashboard

Ranolazine

Brand: ASPRUZYO SPRINKLE · 1.9M Part D claims (CY24) · 559K beneficiaries · First FDA approval: 2019-02-27

20 generic mfrs 0 plans require PA

Low NADAC$0.165

→

Avg plan cost$0.218

Part D spend $162.9M 1× spread, current vs floor

Class share

100%

of class CY24 spend

View profile →

Class summary at a glance.

Every drug in this class, ranked by Part D spend.

Related questions.